Administrative Core

项目概要 - 行政核心 行政核心将监督 P01 补助金的行政和财务活动。整体 行政核心的目标是提供集中的科学、行政和财务服务 管理和监督我们的计划项目 (P01) 赠款，题为“功能基因组学和 DEC-Tec 识别生殖细胞特异性避孕药。”行政核心将 1) 促进内部科学互动 P01 资助团队以及我们的 P01 团队和避孕领域其他研究人员之间的合作，2) 带领P01研究人员保持高质量、成功的研究和核心活动，并履行他们的职责 具体目的和目标，以及 3) 促进可逆男性和女性避孕药具进入 临床试验。行政核心将为跟踪赠款资金的使用情况提供支持并准备所有 与 P01 相关的报告和未来的赠款提交。 Martin M. Matzuk 博士将担任主要负责人 负责行政核心的人员将提供行政和科学管理 P01 拨款，并将负责与研究优先事项或问题相关的政策事项的决定 项目或核心范围内以及 P01 补助金的整体运作。研究咨询 委员会（多学科内部和外部科学和行政成员和领导）将 向 Matzuk 博士、项目和核心提供建议和指导。 Matzuk 博士每月都会收到以下建议： 运营委员会讨论集团内部资源分配和资金拨付的具体情况 用于额外或替换人员、设备或其他需求。行政核心将协调 研究咨询委员会（RAC）年会。 RAC 将指导每个项目和 DEC-Tec 核心关于所选避孕目标的“进行”与“不进行”的决定、后续目标 筛查和小分子避孕药开发计划。此外，行政核心将 协调 RAC 半年一次的电话会议。行政支持将由两个人提供 有才华的专业人士。药物发现中心业务经理 John W. Nelson 博士和 高级赠款专家维罗妮卡·阿吉拉尔 (Veronica Aguilar) 将提供多项行政和财务管理服务 服务。行政核心将位于贝勒卡伦大楼二楼，交通便利 医学院 (BCM) 靠近 BCM 项目研究人员。所有项目负责人和核心人员 包括大阪大学在内的董事们将能够接触到财务、人事、人际网络和 计算机服务。这三个项目和核心 B (DEC-Tec) 将平等地利用管理核心。的 行政核心和 RAC 将指导 P01 项目和核心领导者做出推进的关键决策 或停止每项避孕药具开发活动，并将对该 P01 的成功做出重大贡献 拨款提案并创造多种新型生殖细胞特异性避孕药。

PROJECT SUMMARY - ADMINISTRATIVE CORE The Administrative Core will oversee the administrative and financial activities of the P01 grant. The overall objective of the Administrative Core is to provide centralized scientific, administrative, and financial management and oversight of our program project (P01) grant entitled “Functional genomics and DEC-Tec to identify germ cell–specific contraceptives.” The Administrative Core will 1) foster scientific interactions within the P01 grant team and between our P01 team and other investigators working in the field of contraception, 2) lead the P01 investigators to maintain high-quality, successful research and core activities and fulfill their Specific Aims and objectives, and 3) promote the movement of reversible male and female contraceptives into clinical trials. The Administrative Core will provide support for tracking grant fund utilization and prepare all reports and future grant submissions associated with the P01. Dr. Martin M. Matzuk will be the primary individual responsible for the Administrative Core, will provide administrative and scientific management of the P01 grant, and will be responsible for decisions regarding policy matters relating to research priorities or issues within the Projects or Cores as well as the overall operation of the P01 grant. The Research Advisory Committee (multidisciplinary internal and external scientific and administrative members and leaders) will provide advice and direction to Dr. Matzuk, Projects, and Cores. Dr. Matzuk will be advised monthly by the Operations Committee regarding the specifics of resource allocation within the group and fund disbursement for additional or replacement personnel, equipment, or other needs. The Administrative Core will coordinate the annual meeting of the Research Advisory Committee (RAC). The RAC will guide each Project and the DEC-Tec Core on decisions of “Go” versus “No Go” for the contraceptive targets chosen, follow-up targets to screen, and the small-molecule contraceptive development program. Additionally, the Administrative Core will coordinate a semi-annual conference call meeting of the RAC. Administrative support will be furnished by two talented professionals. Dr. John W. Nelson, Business Manager in the Center for Drug Discovery, and Ms. Veronica Aguilar, a Senior Grants Specialist, will provide multiple administrative and financial management services. The Administrative Core will be conveniently located on the 2nd floor of the Cullen Building at Baylor College of Medicine (BCM) in close proximity to the BCM Project Investigators. All Project Leaders and Core Directors, including those at Osaka University, will have access to financial, personnel, networking, and computer services. The three Projects and Core B (DEC-Tec) will utilize the Administrative Core equally. The Administrative Core and RAC will guide the P01 Project and Core Leaders on critical decisions for advancing or halting each contraceptive development campaign and will contribute significantly to the success of this P01 grant proposal and the creation of multiple novel germ cell-specific contraceptives.